INTRODUCTION {#sec1-1}
============

Multiple-drug resistance (MDR) is developed in microorganisms against two or more antibiotics concomitantly due to either production of bacterial enzymes against them, modification in bacterial penicillin-binding proteins, their extrusion by efflux pump or mutations in transferable genes to other bacteria through mobile genetic elements.[@ref1]

Most Gram-negative microbes like *E. coli* are resistant to various antibiotics classes including penicillins, cephalosporin, macrolides and aminoglycosides. Such MDR infections are difficult to treat in compromised paediatric patients which may lead to severe consequences like delayed treatment, prolonged hospitalization, complications, repeated hospital visits and even deaths if could not be managed.[@ref2]

Carbapenems have a strong affinity for the penicillin-binding proteins present on bacterial membrane and are stable against extended-spectrum beta-lactamase and therefore shows high permeability in the bacterial outer membrane.[@ref3] As the bacteria producing carbapenemases have begun to emerge, MDR infections are becoming more formidable challenge.[@ref4]

Carbapenem resistant *E. coli* has now considered among most important nosocomial pathogens that can cause a variety of infections including urinary tract infections (UTI), intestinal and extra-intestinal ailments like diarrhoea and neonatal meningitis.[@ref5] The carbapenems are regarded as an empirical treatment choice for all severe infections due to AmpC and extended-spectrum β-lactamase producing *E. coli*. An increase in the prevalence of the above diseases has been documented in recent years with wide variations in incidence among different regions of the world.[@ref6]

In the US, *E. coli* induced UTIs among paediatric patients to result in approximately eight million health practitioner visits per year.[@ref7] Therapeutic options for the treatment of such bacteria are now limited, and the delays in the detection of carbapenemase production by bacteria mostly leads to the treatment failure, prolonged hospital stay, increased morbidity, mortality and healthcare cost.[@ref8] Thus, evaluation of the antimicrobial resistance pattern of carbapenemase producing *E. coli* in local paediatric patients has been warranted. We aimed the study to evaluate the incidence of multi-drug resistant carbapenemase producing *E. coli* in paediatric patients attending a tertiary care hospital of Lahore, Pakistan. Likewise, the patient's statistic information is a valuable supplement to sensitivity data in distinguishing patient groups at high danger of infection.

METHODS {#sec1-2}
=======

This prospective study was carried out on *E. coli* from all of the pathological samples received at the Department of Microbiology from admitted and ambulatory patients attending hospital, received at the Department of Microbiology, The Children's Hospital Lahore from April 2017 to August 2018 after approval from the institutional ethical committee. We processed a total number of 52,163 specimens for 17 months for the isolation of carbapenemase producing *E. coli*.

The specimens of blood, ear swab tip, central venous pressure (CVP) tip, peritoneal dialysis (PD) catheter, pus, urine, tracheal secretion, cerebrospinal fluid (CSF), endotracheal tube (ETT), and wound swab were cultured on the Blood and MacConkey agar plates. After incubation, the strains were identified morphologically and by using Gram's stain, various biochemical tests and API 20 E.[@ref9] Phenotyping for carbapenemase detection in *E. coli* in the specimen was done by the modified Hodge test (MHT) and combined disc test (CDT). The appearance of clover leaf-like indentation showed MHT positive carbapenemase producing *E. coli*.[@ref10] The non-repetitive isolates, resistant to any of the carbapenem drug were included from the study. The demographic data of the enrolled cases was obtained from the patient files.

The data were analyzed by using SPSS version 23.0. Gender was compared for output with different wards, specimens and outcomes like mortality and discharge by using the Chi-square test. A p-value \<0.05 was considered significant. Friedman's test was employed to compare the difference in the effect of antibiotics on the strains of carbapenemase producing *E. coli*.

RESULTS {#sec1-3}
=======

We isolated a total of 6,468 (12.3%) different bacterial isolates out of which 1,552 (24%) were identified as *E. coli*. Resistance against carbapenems was observed in 245/1552 (16%) isolates, amongst which 113/245 (46%) were found to be CP by MHT and CDT.

The highest number of isolated bacterial strains was 42 (37.2%) from urine and 40 (35.4%) from the blood. There were 22 (19.5%) samples collected from the neonatal unit, followed by 15 (13.3%) from oncology and 14 (12.4%) from ICUs. A total of 56 (49.6%) CP strains were recovered from the females while 57 (50.4%) from male patients. The overall outcome showed that 73 (65%) patients were discharged after successful treatment while 23 (20%) patients left against the medical advice (LAMA). There were 17 (15%) cases of mortality. No statistical association (p\>0.05) was found between the gender with the outcome, specimen and wards ([Table-I](#T1){ref-type="table"}).

###### 

Demographic data of patients infected with CP *E. coli* infections (n=113).

  Specimen                             Frequency (n)     Percentage (%)
  ------------------------------------ ----------------- ------------------
  Blood                                42                37.20%
  Ear Swab Tip                         3                 2.70%
  CVP Tip                              4                 3.50%
  PD Catheter                          4                 3.50%
  Pus                                  6                 5.30%
  Urine                                40                35.40%
  Tracheal secretion                   2                 1.80%
  CSF                                  9                 8%
  ETT                                  1                 0.90%
  Wound Swab                           2                 1.80%
                                                         
  *Wards*                              *Frequency (n)*   *Percentage (%)*
                                                         
  Neonatal Unit                        22.0              19.5%
  Development Ward                     2.0               1.8%
  Surgery Ward                         4.0               3.5%
  All Intensive Care Units (ICUs)      14.0              12.4%
  Medical Emergency                    2.0               1.8%
  Haematology/Oncology Unit            15.0              13.3%
  Cardiology Ward                      1.0               0.9%
  Outdoor Patients (OPD)               7.0               6.2%
  Urology Ward                         3.0               2.7%
  General Medical Unit-I               3.0               2.7%
  General Medical Unit-II              11.0              9.7%
  General Medical Unit-III             4.0               3.5%
  General Medical Unit-IV              3.0               2.7%
  Nephrology Ward                      15.0              13.3%
  Gastroenterology Ward                3.0               2.7%
  Neurology ward                       1.0               0.9%
  Neuro-Surgery ward                   3.0               2.7%
                                                         
  *Gender*                             *Frequency (n)*   *Percentage (%)*
                                                         
  Female                               56                49.6%
  Male                                 57                50.4%
                                                         
  *Outcome*                            *Frequency (n)*   *Percentage (%)*
                                                         
  Discharge                            73                65%
  Death                                17                15%
  LAMA (left against medical advice)   23                20%

Antibiogram was determined by the Kirby Bauer disc diffusion method. The antibiotics used were those as given in [Table-II](#T2){ref-type="table"}. The diameter of each zone of inhibition was identified and interpreted as sensitive, intermediate or resistant as described in CLSI guidelines.[@ref10] E-test was also used to measure the minimum inhibitory concentration of anti-microbial susceptibility of *E. coli* against colistin. The intersection point of the drop-shaped inhibition zone and the graded E-strip showing the inhibitory concentration of colistin was interpreted according to CLSI. All strains showing lower susceptibility to carbapenems like imipenem and meropenem were screened to be CP by using MHT and CDT.[@ref10]

###### 

Antibiogram of carbapenemase producing *E. coli* (n=113).

  Antibiotics[\*](#t2f1){ref-type="table-fn"}   Resistant   Sensitive   Intermediate              
  --------------------------------------------- ----------- ----------- -------------- ------ --- -----
  ***Cephalosporin***                                                                             
  Cefoxitin                                     95          84.1        12             10.6   6   5.3
  Cefuroxime                                    109         96.5        4              3.5    0   0.0
  Cefixime                                      110         97.3        3              2.7    0   0.0
  Ceftazidime                                   113         100.0       0              0.0    0   0.0
  Ceftriaxone                                   111         98.2        2              1.8    0   0.0
  Cefotaxime                                    113         100.0       0              0.0    0   0.0
  Cefepime                                      104         92.0        5              4.4    4   3.5
  ***Aminoglycosides***                                                                           
  Amikacin                                      96          85.0        17             15.0   0   0.0
  Gentamycin                                    108         95.6        5              4.4    0   0.0
  Tobramycin                                    110         97.3        3              2.7    0   0.0
  ***Polypeptide Polymyxin Antibiotics***                                                         
  Colistin                                      89          78.8        18             15.9   6   5.3
  ***Quinolones***                                                                                
  Nalidixic acid                                108         95.6        5              4.4    0   0.0
  ***Fluoroquinolones***                                                                          
  Levofloxacin                                  108         95.6        5              4.4    0   0.0
  Moxifloxacin                                  112         99.1        0              0.0    1   0.9
  Ciprofloxacin                                 106         93.8        5              4.4    2   1.8
  Norfloxacin                                   102         90.3        11             9.7    0   0.0
  ***Monobactams***                                                                               
  Aztreonam                                     107         94.7        6              5.3    0   0.0
  ***Nitrofurans***                                                                               
  Nitrofurantoin                                92          81.4        19             16.8   2   1.8
  ***Carbapenems***                                                                               
  Imipenem                                      105         92.9        4              3.5    4   3.5
  Meropenem                                     103         91.2        5              4.4    5   4.4
  ***Others***                                                                                    
  Fosfomycin                                    101         89.4        12             10.6   0   0.0
  Pipemidic acid                                112         99.1        1              0.9    0   0.0
  ***Combination Antibiotics***                                                                   
  Co-amoxiclav                                  109         96.5        4              3.5    0   0.0
  Piperacillin-tazobactam                       105         92.9        2              1.8    6   5.3
  Co-trimoxazole                                110         97.3        3              2.7    0   0.0
  Cefoperazone-sulbactam                        102         90.3        4              3.5    7   6.2

p\<0.05 using Friedman test used to see the difference in the effects of antibiotics

In antimicrobial susceptibility testing, colistin sulphate (15.9%) and nitrofurantoin (16.8%) were found to be the most effective antibiotic in vitro followed by amikacin (15%) and fosfomycin (10.6%). The overall MDR among *E. coli* strains was found to be 93.26%. The bacterial isolates were found to be 100% resistant to cefotaxime and ceftazidime. Lower susceptibility rates were seen for cefoperazone-sulbactam (3.5%) and piperacillin-tazobactam (1.8%). The p-value \<0.05 indicated that there was a difference in the effects of antibiotics ([Table-II](#T2){ref-type="table"}).

DISCUSSION {#sec1-4}
==========

In this study, we included the patients received at a prominent paediatric hospital at Lahore, which is serving such patient population from all over the Punjab province and reported 16% CP *E. coli*. A study at Indian hospital identified 22 *E. coli* isolates, all of which showed complete resistance against carbapenem antibiotics.[@ref11] In another study in Los Angeles, USA, eleven *E. coli* strains were identified out of which 5 (45.4%) were CP.[@ref12] A study conducted at Karachi hospital reported the maximum cases of CP from urine samples (40%).[@ref13] However, in our study, the maximum of CP *E. coli* were isolated from blood samples (37.2%).

In our study, only 6.2% CP *E. coli* strains were isolated from outpatients while 93.8% from hospitalized patients which is in contrast to an Iranian study, where a lower frequency of *E. coli* (33%) was isolated from inpatients than from outpatients (66%).[@ref14] A study including seven US hospitals showed that 51% of MDR CP *E. coli* were isolated from ICUs followed by medical ward (38%) and surgery unit (20%).[@ref7] These remarkably high prevalence values are unprecedented with the frequency of our study in which only 12.4% cases were from ICUs, 18.6% from general medical and surgery ward. The reason for the higher risk of nosocomial infections in ICUs patients may be due to the critical condition and suppressed immunity of the patients needing intensive care.

The frequency of CP *E. coli* strains was higher in males 57 (50.4%) than females 56 (49.6%) in this study. Contrarily, *E. coli* infection was found to be higher in females (71%) than in male patients (55%) in another study.[@ref15] The reason for such a contradiction with our result may be due to the fact that the parents in the developing countries bring male children more to the hospital in comparison to the female.

In a study conducted at St. Louis teaching hospital, the mortality rate of patients with MDR *E. coli* infection was 61.9%which is quite high in comparison to our study (15%).[@ref16] Mortality related to such infections can be predetermined to be present with patients acquiring nosocomial infections during the hospital stay or due to interventions like surgeries.

The present study showed an alarming increased rate in MDR in *E. coli* (93.26%) as compared to other study carried out in Sudan (57%).[@ref17] A US study reported 92% *E. coli* to be sensitive to colistin, which is higher than our study (15.9%).[@ref18] The current study expressed that most of *E. coli* were concurrently MDR against different antibiotic classes like cephalosporins, aminoglycosides, fluoroquinolones and carbapenems. Similar reports by others showed higher resistance to these antibiotics.[@ref14] A possible reason for the high co-resistance found in such strains could be the modification of bacterial genes; hence producing enzymes like metallo-beta-lactamases, resulting in increased resistance. A study from India also reported high resistance to CP strains to aminoglycosides, beta-lactams, sulphonamides and fluoroquinolones.[@ref11] Various factors like polypharmacy, lesser trends of using targeted antibiotics and not promoting bacterial identification tests contribute towards higher resistance patterns of MDR *E. coli*.

Sahm *et al*. reported 7.1% MDR *E. coli* in 2000.[@ref19] A very high incidence of metallo-beta-lactamase (97.8%) producing bacteria resistant to carbapenems, aminoglycosides, cephalosporin and fluoroquinolones have been reported in paediatric patients.[@ref20] The relevance of genetic background and the MDR bacteria with a high level of resistance to carbapenems, co-amoxiclav, ampicillin, aztreonam and cephalosporins have been reported amongst the paediatric patients of Pakistan.[@ref21] Pharmacists can play an integral role in depressing the rapid spread of resistance in pathogens among paediatric patients by involving themselves at clinical levels and promoting rational use of drugs, decreasing the use of un-targeted potent antibiotics as empirical therapy as well as polypharmacy and facilitating the formulation of future antibiotic policies. The study was conducted in the largest tertiary care hospital of Punjab; nevertheless, it was not possible to obtain data on regional and locality basis, a limitation of this study.

CONCLUSION {#sec1-5}
==========

This study demonstrated high number of CP producing *E. coli* from clinical samples of admitted and outpatients from a tertiary care paediatric hospital. The pathogens were combatively less resistant to colistin and amikacin, but some other resistance mechanism could lead to their reduced sensitivity. This high rate of resistance could be a direct result of increased trends towards the use of untargeted potent antibiotics as well as that of antibiotic polypharmacy in hospitals as empirical therapy. The understanding of mechanisms of horizontal transfer of genes can be helpful in the development of new policies to fight this health issue of MDR infections.
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